Table 2.
Open in new tab

Anti–Plasmodium falciparum Circumsporozoite Protein (CS) Antibody Avidity Index on the Day of Challenge in the According-to-Protocol Population

VariableSubjects, No.Anti-CS Antibody Antigen Target
Repeat region (NANP)Full lengthC-term Pf16
Overall
 Fx017M schedule300.58 ± 0.160.68 ± 0.100.72 ± 0.08
 012M schedule160.48 ± 0.130.55 ± 0.080.50 ± 0.13
 P Valuea.0367<.0001<.0001
Fx017M scheduleb
 Protected260.59 ± 0.160.68 ± 0.100.72 ± 0.08
 Not protected40.50 ± 0.130.70 ± 0.080.71 ± 0.11
012M scheduleb
 Protected100.51 ± 0.140.55 ± 0.080.51 ± 0.13
 Not protected60.44 ± 0.090.55 ± 0.060.48 ± 0.12
VariableSubjects, No.Anti-CS Antibody Antigen Target
Repeat region (NANP)Full lengthC-term Pf16
Overall
 Fx017M schedule300.58 ± 0.160.68 ± 0.100.72 ± 0.08
 012M schedule160.48 ± 0.130.55 ± 0.080.50 ± 0.13
 P Valuea.0367<.0001<.0001
Fx017M scheduleb
 Protected260.59 ± 0.160.68 ± 0.100.72 ± 0.08
 Not protected40.50 ± 0.130.70 ± 0.080.71 ± 0.11
012M scheduleb
 Protected100.51 ± 0.140.55 ± 0.080.51 ± 0.13
 Not protected60.44 ± 0.090.55 ± 0.060.48 ± 0.12

Data are mean values ±SDs, unless otherwise indicated. Challenge was performed approximately 3 weeks after the last dose.

Abbreviations: Fx017M, delayed fractional dose, comprising a 0.5-mL dose of RTS,S/AS01B followed 1 month later by a 0.5-mL dose of RTS,S/AS01B, followed 6 months later by a 0.1-mL dose of RTS,S/AS01B; 012M, 0- , 1-, and 2-month standard schedule comprising 3 doses of 0.5 mL of RTS,S/AS01B given 1 month apart.

a By the 2-sample Student t test, for comparisons for each antibody target.

b “Protected” denotes subjects who were protected after the first CHMI. “Not protected” denotes subjects who were not protected after the first CHMI.

Table 2.
Open in new tab

Anti–Plasmodium falciparum Circumsporozoite Protein (CS) Antibody Avidity Index on the Day of Challenge in the According-to-Protocol Population

VariableSubjects, No.Anti-CS Antibody Antigen Target
Repeat region (NANP)Full lengthC-term Pf16
Overall
 Fx017M schedule300.58 ± 0.160.68 ± 0.100.72 ± 0.08
 012M schedule160.48 ± 0.130.55 ± 0.080.50 ± 0.13
 P Valuea.0367<.0001<.0001
Fx017M scheduleb
 Protected260.59 ± 0.160.68 ± 0.100.72 ± 0.08
 Not protected40.50 ± 0.130.70 ± 0.080.71 ± 0.11
012M scheduleb
 Protected100.51 ± 0.140.55 ± 0.080.51 ± 0.13
 Not protected60.44 ± 0.090.55 ± 0.060.48 ± 0.12
VariableSubjects, No.Anti-CS Antibody Antigen Target
Repeat region (NANP)Full lengthC-term Pf16
Overall
 Fx017M schedule300.58 ± 0.160.68 ± 0.100.72 ± 0.08
 012M schedule160.48 ± 0.130.55 ± 0.080.50 ± 0.13
 P Valuea.0367<.0001<.0001
Fx017M scheduleb
 Protected260.59 ± 0.160.68 ± 0.100.72 ± 0.08
 Not protected40.50 ± 0.130.70 ± 0.080.71 ± 0.11
012M scheduleb
 Protected100.51 ± 0.140.55 ± 0.080.51 ± 0.13
 Not protected60.44 ± 0.090.55 ± 0.060.48 ± 0.12

Data are mean values ±SDs, unless otherwise indicated. Challenge was performed approximately 3 weeks after the last dose.

Abbreviations: Fx017M, delayed fractional dose, comprising a 0.5-mL dose of RTS,S/AS01B followed 1 month later by a 0.5-mL dose of RTS,S/AS01B, followed 6 months later by a 0.1-mL dose of RTS,S/AS01B; 012M, 0- , 1-, and 2-month standard schedule comprising 3 doses of 0.5 mL of RTS,S/AS01B given 1 month apart.

a By the 2-sample Student t test, for comparisons for each antibody target.

b “Protected” denotes subjects who were protected after the first CHMI. “Not protected” denotes subjects who were not protected after the first CHMI.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close